← Eichor
Study identifier: NCT06192160 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Condition: Pulmonary Tuberculosis  ·  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

PhasePhase 2
Planned participants315
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary tuberculosis (TB). A5409 hypothesizes that novel regimens for the treatment of pulmonary tuberculosis will result in superior early efficacy, as determined by longitudinal mycobacteria growth indicator tube (MGIT) liquid culture time to positivity (TTP) measurements over the first 6 weeks of treatment, and will have acceptable safety and tolerability over 8 weeks of treatment relative to standard of care \[(SOC) isoniazid/rifampicin/pyrazinamide/ethambutol (HRZE)\]. The study will run for 52 weeks, inclusive of 26 weeks of TB treatment comprised of 8 weeks of study treatment (experimental or SOC, based on treatment arm assignment) followed by 18 weeks of SOC continuation phase treatment with 45 participants in each experimental treatment arm and at least 90 participants in the SOC arm.

This description comes directly from the study's public registry record.

Talk to the study team

Radojka Savic, PharmD, PhD  ·  415-502-0640  ·  rada.savic@ucsf.edu

Kelly Dooley, MD, PhD  ·  615-322-8972  ·  kelly.e.dooley@vumc.org

Always discuss trial participation with your own doctor first.

Locations (29)

12701, Gaborone CRSGaborone, BotswanaRecruiting
12201, Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRSPorto Alegre, BrazilRecruiting
12101, Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRSRio de Janeiro, BrazilRecruiting
30022, Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRSPort-au-Prince, HaitiNot Yet Recruiting
31730, GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRSPort-au-Prince, HaitiNot Yet Recruiting
31441, Byramjee Jeejeebhoy Medical College (BJMC) CRSPune, IndiaNot Yet Recruiting
12601, Moi University Clinical Research Center (MUCRC) CRSEldoret, KenyaRecruiting
12501, Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRSKericho, KenyaRecruiting
30301, Blantyre CRSBlantyre, MalawiNot Yet Recruiting
12001, Malawi CRSLilongwe, MalawiNot Yet Recruiting
32078, Nutrición-Mexico CRSMexico City, MexicoNot Yet Recruiting
11301, Barranco CRSLima, PeruRecruiting

+ 17 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06192160